US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

21.68

+0.84004.03%

Post-market: 21.680.00000.00%16:10 EDT

Volume:365.78K

Turnover:7.88M

Market Cap:1.42B

PE:-7.75

High:21.96

Open:20.84

Low:20.54

Close:20.84

52wk High:24.25

52wk Low:7.80

Shares:65.47M

Float Shares:47.99M

Volume Ratio:0.78

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.7971

EPS(LYR):-2.5230

ROE:-32.34%

ROA:-21.09%

PB:2.76

PE(LYR):-8.59

Loading ...

Overview Company News Filings

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile

THOMSON REUTERS

Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc

THOMSON REUTERS

Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC

Bicara Therapeutics management to meet with Cantor

Bicara CEO Claire Mazumdar sells $300,000 common shares

Bicara Therapeutics Highlights Momentum in Earnings Call

Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum

Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38

Bicara grants new CCO option for 282,240 shares at $22.58 each

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics files initial beneficial ownership statement for CMO William Schelman

Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley

Bicara Therapeutics Inc. (BCAX) Gets a Buy from Morgan Stanley

Bicara Therapeutics Initiated at Buy by Guggenheim

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bicara Therapeutics posts corporate deck spotlighting ficerafusp alfa for HPV-negative head and neck cancer

Stock Track | Bicara Therapeutics Plunges 11.43% in Pre-Market After Wider-Than-Expected Q1 Loss

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":21.68,"timestamp":1779480000000,"preClose":20.84,"halted":0,"volume":365780,"hourTrading":{"tag":"盘后","latestPrice":21.68,"preClose":21.68,"latestTime":"16:10 EDT","volume":32597,"amount":706702.96,"timestamp":1779480604871,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04030710172744721,"floatShares":47985886,"shares":65467200,"eps":-2.797107,"marketStatus":"Market Closed","change":0.84,"latestTime":"05-22 16:00:00 EDT","open":20.84,"high":21.96,"low":20.535,"amount":7879235,"amplitude":0.068378,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.797107,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":20.84,"preHourTrading":{"tag":"盘前","latestPrice":20.81,"preClose":20.84,"latestTime":"09:29 EDT","volume":28,"amount":580.730024,"timestamp":1779456556038,"change":-0.03,"changeRate":-0.00144,"amplitude":0.112284},"postHourTrading":{"tag":"盘后","latestPrice":21.68,"preClose":21.68,"latestTime":"16:10 EDT","volume":32597,"amount":706702.96,"timestamp":1779480604871,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7750778298339879,"impliedVol":0.2389,"impliedVolPercentile":0.3586},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":47985886,"roa":"-21.09%","roe":"-32.34%","lyrEps":-2.523003,"volumeRatio":0.7750778298339879,"shares":65467200,"dividePrice":0,"high":21.96,"amplitude":0.068378,"preClose":20.84,"low":20.535,"week52Low":7.8,"pbRate":"2.76","week52High":24.25,"institutionHeld":0,"latestPrice":21.68,"eps":-2.797107,"divideRate":0,"volume":365780,"delay":0,"ttmEps":-2.797107,"open":20.84,"prevYearClose":16.83,"prevWeekClose":20.23,"prevMonthClose":21.58,"prevQuarterClose":19.89,"fiveDayClose":20.23,"twentyDayClose":22.65,"sixtyDayClose":16.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.4667,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4667,"analysts":15,"updateTime":1778558400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-05-22","current":-7.750865,"percent":0.562648,"low":-22.704836,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"high":-5.144536,"avg":-10.540701,"sd":4.382994,"marketCap":1369268567},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567}],"updateTime":1779664744549},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2637345356","title":"Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637345356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637345356?lang=en_us&edition=fundamental","pubTime":"2026-05-23 00:01","pubTimestamp":1779465665,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGIO","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637639323","title":"Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2637639323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637639323?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:47","pubTimestamp":1779407257,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On May 21, 2026, Bicara Therapeutics reported three-year follow-up data f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317357","title":"Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637317357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035731","title":"Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637035731?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352703","title":"Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352703","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352703?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:01","pubTimestamp":1779397317,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics reported three-year follow-up results from its Phase 1/1b study of ficerafusp alfa with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck cancer.The results were slated for presentation at the 2026 ASCO Annual Meeting, with the updated dataset pointing to durable responses and longer-term survival that the company attributed to TGF-β inhibition.The readout underpins the company’s ongoing FORTIFI-HN01 pivotal program using the selected weekly dose regimen in combination with pembrolizumab.Bicara also plans to start a separate study in the third quarter of 2026 to test a loading-dose regimen followed by less frequent maintenance dosing to support longer-term treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL49cbby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352019","title":"Bicara Therapeutics management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352019?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397225,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on May 26 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878696","title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878696","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878696?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:08","pubTimestamp":1779307736,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics CEO and director Claire Mazumdar cut her stake to 362,152 shares on May 18.The filing shows sales of 15,000 shares at weighted average prices of USD 19.96 and USD 20.35.She also acquired 15,000 shares at USD 3.79 through an option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL3wS0Wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817130","title":"Bicara Therapeutics Highlights Momentum in Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817130","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636817130?lang=en_us&edition=fundamental","pubTime":"2026-05-20 16:41","pubTimestamp":1779266518,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Bicara Therapeutics’ latest earnings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-highlights-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-highlights-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636006760","title":"Bicara Therapeutics’ Earnings Call Highlights Ficera Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2636006760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636006760?lang=en_us&edition=fundamental","pubTime":"2026-05-19 08:19","pubTimestamp":1779149954,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (($BCAX)) has held its Q1 earnings call. Read on for the main highlights of the call. Bicara Therapeutics’ latest earnings...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-earnings-call-highlights-ficera-momentum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-earnings-call-highlights-ficera-momentum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800963","title":"Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800963","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800963?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:25","pubTimestamp":1779135911,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, president and COO, sold 12,500 shares of Bicara Therapeutics common stock on May 15 at a weighted average price of USD 20.29.He also exercised stock options for 8,000 shares at USD 3.79 on the same day.He ended the day with 191,641 shares of common stock beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL7sGTvB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara President, COO Ryan Cohlhepp sells 12,500 shares for $253,649.38","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278262","title":"Bicara grants new CCO option for 282,240 shares at $22.58 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278262","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278262?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:32","pubTimestamp":1778675578,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics granted Chief Commercial Officer Christopher Sarchi a non-qualified stock option for 282,240 shares, effective May 8, 2026.Exercise price set at USD 22.58 per share, matching Nasdaq closing price on May 8.Vesting set at 25% on first anniversary of start date, remaining shares in 12 equal quarterly installments, subject to continued service.Award made under Bicara 2026 Inducement Plan, adopted by board in January 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3j8VkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4588","SG9999014039.USD","BK4139","BCAX","BK4112","IE00BN0W2V16.EUR","NDAQ","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635825447","title":"Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635825447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635825447?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA4FHRHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782729","title":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782729","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782729?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:30","pubTimestamp":1778675400,"startTime":"0","endTime":"0","summary":"BOSTON, May  13, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293981/0/en/Bicara-Therapeutics-Announces-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B12V2V27.USD","IE00BYQNZ168.SGD","LU1023057109.AUD","BK4552","SG9999011746.SGD","01698","BK4563","BK4526","BK4531","LU2039709279.SGD","BK4565","BK4548","BCAX","LU0828238088.HKD","LU0456842615.SGD","BK4108","BK4535","IE00BYTNYN87.SGD","LU0509642566.USD","TME","BK4571","LU0359202008.SGD","LU0359201612.USD","BK4509","BK4139","LU0269904917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635420442","title":"Bicara Therapeutics files initial beneficial ownership statement for CMO William Schelman","url":"https://stock-news.laohu8.com/highlight/detail?id=2635420442","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635420442?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:03","pubTimestamp":1778616193,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Chief Medical Officer William Schelman reported stock options for 175,000 shares, including 150,000 at USD 16.61 and 25,000 at USD 16.76, in an initial Form 3 filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL56byDJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635246376","title":"Bicara Therapeutics Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635246376","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635246376?lang=en_us&edition=fundamental","pubTime":"2026-05-13 00:18","pubTimestamp":1778602680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 12, 2026 12:18 ET (16:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218495","title":"Bicara Therapeutics Inc. (BCAX) Gets a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218495?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:58","pubTimestamp":1778583498,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer maintained a Buy rating on Bicara Therapeutics Inc. yesterday and set a price target of $37.00. The company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bicara-therapeutics-inc-bcax-gets-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bicara-therapeutics-inc-bcax-gets-a-buy-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1064131342.USD","LU1162221912.USD","IE00BKVL7J92.USD","BK4585","LU2023251221.USD","LU0098860793.USD","LU1791710582.SGD","LU2271345857.HKD","BK4534","BCAX","LU0390134368.USD","LU1668664300.SGD","LU2264538146.SGD","BK4581","LU1074936037.SGD","LU2347655156.SGD","BK4139","LU2089284900.SGD","LU0320765646.SGD","LU0106831901.USD","LU0912757837.SGD","LU1732800096.USD","LU0795875169.SGD","LU1989772923.USD","LU0528227936.USD","BK4127","LU1244550221.USD","LU1791710400.SGD","LU0314104364.USD","LU2357305700.SGD","LU2111349929.HKD","LU0795875086.SGD","LU0006306889.USD","LU0158827781.USD","LU0267386448.USD","LU1989772840.SGD","LU1548497426.USD","LU0971096721.USD","LU2028103732.USD","LU1244550494.USD","LU1244550577.SGD","LU1988902786.USD","LU2133065610.SGD","BK4516","LU0882574139.USD","LU1720051017.SGD","BK4504","IE00BZ1G4Q59.USD","LU1363072403.SGD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634231902","title":"Bicara Therapeutics Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2634231902","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634231902?lang=en_us&edition=fundamental","pubTime":"2026-05-12 02:48","pubTimestamp":1778525280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 14:48 ET (18:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634361342","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2634361342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634361342?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:01","pubTimestamp":1778518877,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicara Therapeutics Inc. (BCAX) and Myomo (MYO) with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-161?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-161?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","LU0029874061.USD","BK4082","LU0128526141.USD","BK4581","BK4585","BCAX","BLSG","BK4137","MYO","BK4139","BK4112","XBI","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634281999","title":"Bicara Therapeutics posts corporate deck spotlighting ficerafusp alfa for HPV-negative head and neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2634281999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634281999?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:45","pubTimestamp":1778503539,"startTime":"0","endTime":"0","summary":"Bicara outlined development strategy for ficerafusp alfa , an EGFR-directed antibody bound to a TGF-β ligand trap, targeting first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma.Phase 1b data for FICERA 1500 mg once weekly with pembrolizumab in HPV-negative, CPS≥1 patients showed confirmed ORR 54%  with CR rate 21% ; median duration of response 21.7 months.Overall survival in that cohort was median 21.3 months with 2-year OS rate 46% at median follow-up 25.2 months.Company highlighted a manageable safety profile for the 1500 mg regimen with no treatment-related deaths, with EGFR-related adverse events common.Pivotal study is underway with interim analysis targeted for mid-2027; additional signal-seeking work planned in other solid tumors starting with metastatic colorectal cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL2DM2h4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142150379","title":"Stock Track | Bicara Therapeutics Plunges 11.43% in Pre-Market After Wider-Than-Expected Q1 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1142150379","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142150379?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:44","pubTimestamp":1778503456,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (BCAX) shares plummeted 11.43% in pre-market trading on Monday, following the release of its first-quarter 2026 financial results.The clinical-stage biopharmaceutical company...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":135,"code":"91000000","status":"200"}]}}